Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4 CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Xiangao Huang, David S Jayabalan, Maurizio Di Liberto, Zhengming Chen, Scott Ely, Roger Pearse, Joseph Lane, Gang Lin, Ruben Niesvizky, Selina Chen-Kiang

Blood (2024) 144 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2024-206115

Published: 2024

Journal Articles

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MDMSc, Daniel W. Sherbenou, MDPhD, Andrew Hammes, MS, Adriana C. Rossi, MDMSc, Ruben Niesvizky, MD, David S Jayabalan, MSc, Scott Ely, MDMPH

Blood (2017) 130 (Supplement 1): 3059.

https://doi.org/10.1182/blood.V130.Suppl_1.3059.3059

Published: 2017

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

Journal Articles

Prolonged early G 1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Xiangao Huang, Maurizio Di Liberto, David Jayabalan, Jun Liang, Scott Ely, Jamieson Bretz, Arthur L. Shaffer, III, Tracey Louie, Isan Chen, Sophia Randolph, William C. Hahn, Louis M. Staudt, Ruben Niesvizky, Malcolm A. S. Moore, Selina Chen-Kiang

Blood (2012) 120 (5): 1095–1106.

https://doi.org/10.1182/blood-2012-03-415984

Published: 2012

Includes: Supplemental data

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Tomer Mark, MD, Morton Coleman, MD, David S Jayabalan, BSMS, Roger Pearse, MD/PhD, Faiza Zafar, PA, Scott Ely, MD, MPH, Megan C. Manco, Mary Crann, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2009) 114 (22): 1861.

https://doi.org/10.1182/blood.V114.22.1861.1861

Published: 2009

Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1877.

https://doi.org/10.1182/blood.V114.22.1877.1877

Published: 2009

Journal Articles

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

Jia Ruan, MD, PhD, Peter Martin, Richard R Furman, MD, Julie M. Vose, MD, Ann LaCasce, MD, Ying-Kuen K. Cheung, PhD, Jennifer O'Loughlin, Rebecca Elstrom, MD, Ruben Niesvizky, MD, Amy Chadburn, MD, Scott Ely, MD, Ethel Cesarman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2009) 114 (22): 2682.

https://doi.org/10.1182/blood.V114.22.2682.2682

Published: 2009

Journal Articles

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.

Hearn J. Cho, MD, PhD, Anna Mei, Tricia Nardiello, Maurizio DiLiberto, Xiangao Huang, Jennifer E Amengual, MD, Achim Jungbluth, MD, Scott Ely, MD, MPH, Ruben Niesvizky, MD, David S Jayabalan, BSMS, Lloyd Old, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1795.

https://doi.org/10.1182/blood.V114.22.1795.1795

Published: 2009

Journal Articles

ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.

Peter Martin, Amy Chadburn, MD, Wayne Tam, Lauren Tyrell, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Morton Coleman, Scott Ely, MD, MPH, Daniel M. Knowles, John P. Leonard, Richard R Furman

Blood (2009) 114 (22): 4686.

https://doi.org/10.1182/blood.V114.22.4686.4686

Published: 2009

Journal Articles

The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.

Tomer Mark, Megan C. Manco, Maureen Lane, Maureen Ward, Donna Skerrett, Scott Ely, Michael W. Schuster, Tsiporah B Shore, Roger N Pearse, Faiza Zafar, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2009) 114 (22): 4349.

https://doi.org/10.1182/blood.V114.22.4349.4349

Published: 2009

Journal Articles

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Rentian Feng, PhD, Xiangao Huang, PhD, Les Coulton, PhD, Hendrik De Raeve, MD, Maurizio DiLiberto, PhD, Scott Ely, MD, MPH, Guozhi Xiao, PhD, Min Luo, MD, Eline Menu, PhD, Peter Croucher, MD, G. David Roodman, MD, PhD, Karin Vanderkerken, MD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 298.

https://doi.org/10.1182/blood.V114.22.298.298

Published: 2009

Journal Articles

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD, MPH, David S Jayabalan, BSMS, Isan Chen, MD, Keith D. Wilner, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 299.

https://doi.org/10.1182/blood.V114.22.299.299

Published: 2009

Journal Articles

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant MCL Cells for Killing by Proteasome Inhibitor Bortezomib by Activating Cell Cycle-Coupled Apoptosis

Maurizio Di Li berto, Ph.D., Xiangao Huang, Ph.D., Amy Chadburn, M.D., Peter Martin, M.D., Ruben Niesvizky, M.D., Scott Ely, M.D., M.P.H., John P. Leonard, M.D., Selina Chen- Kiang, Ph.D.

Blood (2008) 112 (11): 3624.

https://doi.org/10.1182/blood.V112.11.3624.3624

Published: 2008

Journal Articles

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Tracey Louie, B.Sc., David S Jayabalan, B.Sc., Scott Ely, MD, MPH, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2008) 112 (11): 3678.

https://doi.org/10.1182/blood.V112.11.3678.3678

Published: 2008

Journal Articles

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Blood (2008) 111 (3): 1101–1109.

https://doi.org/10.1182/blood-2007-05-090258

Published: 2008

Includes: Supplemental data

Journal Articles

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Y. Lynn Wang, PhD, Richard Lent, MD, Paul J. Christos, MPH, Joong W. Lee, PhD, Yashpal P. Agrawal, MD/PhD, Susan Matthews, PhD, Scott Ely, MD, Madhu Mazumdar, PhD, Ethel Cesarman, MD, April Rambo, RN, John P. Leonard, MD, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 2737.

https://doi.org/10.1182/blood.V110.11.2737.2737

Published: 2007

NARROW

CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4 CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Prolonged early G 1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.

ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.

The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant MCL Cells for Killing by Proteasome Inhibitor Bortezomib by Activating Cell Cycle-Coupled Apoptosis

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only